Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
复制标题
DOI：
10.3390/v13071364
复制
发表时间：
2021-07-14
期刊：
影响因子：
--
通讯作者：
Douxfils J
中科院分区：
文献类型：
--
作者：
Favresse J;Gillot C;Di Chiaro L;Eucher C;Elsen M;Van Eeckhoudt S;David C;Morimont L;Dogné JM;Douxfils J
抗SARS-CoV-2抗体的中和能力的评估是重要的，因为它们代表了真实的保护性免疫。在这项研究中，我们的目的是测量和比较COVID-19患者和接种疫苗的个体中的中和抗体（NAb）。采用替代病毒中和试验（sVNT）分析了75名COVID-19患者的150份长期样本，并与6种不同的SARS-CoV-2血清学检测方法进行了比较。发现sVNT和假病毒VNT（pVNT）结果之间的一致性是极好的（即，97.2%）。还在接受BNT 162 b2的完整剂量方案的90个个体中评估了NAb应答。在COVID-19患者中，观察到中重度患者与轻度患者的反应更强（p值= 0.0006）。在诊断后长达300天的样本中观察到NAb的缓慢衰减，特别是在中重度患者中（r =-0.35，p值= 0.03）。在接种疫苗的人群中，83.3%的COVID-19初治个体在第一剂后14天呈阳性NAb，在第二剂后7天全部呈阳性，即，在第28天。在先前感染的个体中，所有人在第14天已经对NAb呈阳性。在每个时间点，对于先前感染的个体观察到更强的应答（p值< 0.05）。NAb反应在所有参与者中保持稳定长达56天。与COVID患者相比，接种疫苗的参与者的NAb滴度显著更高。在先前感染疫苗的受者中，一剂疫苗可能足以产生足够的中和抗体。
The evaluation of the neutralizing capacity of anti-SARS-CoV-2 antibodies is important because they represent real protective immunity. In this study we aimed to measure and compare the neutralizing antibodies (NAbs) in COVID-19 patients and in vaccinated individuals. One-hundred and fifty long-term samples from 75 COVID-19 patients were analyzed with a surrogate virus neutralization test (sVNT) and compared to six different SARS-CoV-2 serology assays. The agreement between the sVNT and pseudovirus VNT (pVNT) results was found to be excellent (i.e., 97.2%). The NAb response was also assessed in 90 individuals who had received the complete dose regimen of BNT162b2. In COVID-19 patients, a stronger response was observed in moderate–severe versus mild patients (p-value = 0.0006). A slow decay in NAbs was noted in samples for up to 300 days after diagnosis, especially in moderate–severe patients (r = −0.35, p-value = 0.03). In the vaccinated population, 83.3% of COVID-19-naive individuals had positive NAbs 14 days after the first dose and all were positive 7 days after the second dose, i.e., at day 28. In previously infected individuals, all were already positive for NAbs at day 14. At each time point, a stronger response was observed for previously infected individuals (p-value < 0.05). The NAb response remained stable for up to 56 days in all participants. Vaccinated participants had significantly higher NAb titers compared to COVID patients. In previously infected vaccine recipients, one dose might be sufficient to generate sufficient neutralizing antibodies.
登录
查看更多内容
影响因子：
82.9
作者：
Ebinger JE;Fert-Bober J;Printsev I;Wu M;Sun N;Prostko JC;Frias EC;Stewart JL;Van Eyk JE;Braun JG;Cheng S;Sobhani K
通讯作者：
Sobhani K
影响因子：
5.4
作者：
Figueiredo-Campos P;Blankenhaus B;Mota C;Gomes A;Serrano M;Ariotti S;Costa C;Nunes-Cabaço H;Mendes AM;Gaspar P;Pereira-Santos MC;Rodrigues F;Condeço J;Escoval MA;Santos M;Ramirez M;Melo-Cristino J;Simas JP;Vasconcelos E;Afonso Â;Veldhoen M
通讯作者：
Veldhoen M
影响因子：
8
作者：
McAndrews, Kathleen M.;Dowlatshahi, Dara P.;Kalluri, Raghu
通讯作者：
Kalluri, Raghu
影响因子：
6.8
作者：
Bohn, Mary Kathryn;Loh, Tze Ping;Adeli, Khosrow
通讯作者：
Adeli, Khosrow
影响因子：
12.7
作者：
Favresse, Julien;Cadrobbi, Julie;Douxfils, Jonathan
通讯作者：
Douxfils, Jonathan